Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                 December 6,2005
                Date of Report (Date of earliest event reported)

                                 ANTIGENICS INC
             (Exact name of registrant as specified in its charter)

          DELAWARE                   000-29089                  06-1562417
(State or other jurisdiction        (Commission               (IRS Employer
       of incorporation)            File Number)           Identification No.)

          630 Fifth Avenue, Suite 2100
                New York, NY 10111                               10111
      (Address of principal executive offices)                 (Zip Code)

              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[_]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

[_]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))

Item 2.05 Costs Associated with Exit or Disposal Activities

          On December 6, 2005, Antigenics Inc. issued a press release, attached
hereto as Exhibit 99.1, announcing an update to its business strategies and an
outline of the timeline for the analysis of its Phase 3 Kidney cancer trial. The
content of that press release is incorporated herein by reference.

         As part of these strategies, the Company has terminated approximately
70 employees and has estimated its costs related to these terminations and other
related activities to be approximately $2 million including severance and other
cash costs.

Item 9.01 Financial Statements and Exhibits

         (c) Exhibits

         99.1       Press Release dated December 6, 2005


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    ANTIGENICS INC.

Date: December 6, 2005
                                    By: /s/ Garo H. Armen
                                    Garo H. Armen, Ph.D.
                                    Chairman and Chief Executive Officer

                                  EXHIBIT INDEX

Exhibit No.       Description of Exhibit
-----------       ----------------------
99.1              Press Release dated December 6, 2005